Home » Topics » Regulatory » NMPA

NMPA
RSS

F-647 approved in China

Sep. 22, 2011

First iguratimod product approved in China

Aug. 26, 2011

High-dose EPIAO approved in China to treat chemotherapy-associated anemia

July 14, 2011

Chinese health authorities approve Novo Nordisk's Victoza for type 2 diabetes

March 16, 2011

Hutchison MediPharma begins phase I trial of fruquintinib in China

Feb. 2, 2011

TPIAO approved in China for idiopathic thrombocytopenic purpura

Jan. 26, 2011

Sinovac receives SFDA approval to begin trials of EV-71 vaccine

Dec. 29, 2010

Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction

Dec. 13, 2010

MicuRx files IND for MRX-I antibiotic in China

March 16, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 8, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.